Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and EMBASE databases published through June 1, 2014. A total of 11 studies for ERCC2 rs13181 were selected; these included 3456 glioma cases and 4957 controls.
We conducted a prospective study to investigate the role of ERCC2 gene polymorphisms on the outcome of cisplatin-based treatment in patients with osteosarcoma. A total of 115 patients with osteosarcoma were included in our study. Genotyping of ERCC2 Asn312Asp (rs1799793) and Lys751Gln (rs13181) was performed using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry method. Of the 115 patients, 78 showed complete or partial response to chemotherapy, with a response rate of 67.85%.
We investigate whether three common polymorphisms in ERCC1 and ERCC2 are predictor factors for the chemotherapy response, as well as the clinic outcome of patients with gastric cancer. Between May 2011 and May 2013, 263 patients with gastric cancer who were newly diagnosed by histopathology were enrolled in our study. Genotyping of the ERCC1 rs11615 and rs3212986, and ERCC2 rs1799793 polymorphisms were conducted by the polymerase chain reaction-restriction fragment length polymorphism assay.